This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Clinical effects of high oral dose of donepezil for patients with Alzheimer’s disease in Japan


Nozawa, Motohiro, Ichimiya, Yosuke, Nozawa, Eiko, Utumi, Yushi, Sugiyama, Hideki, Murayama, Norio, Iseki, Eizo, Arai, Heii


Psychogeriatrics: The Official Journal Of The Japanese Psychogeriatric Society, Volume: 9, No.: 2, Pages.: 50-55

Year of Publication



Background: Donepezil 10 mg/day gained approval in Japan in August 2007 for the treatment of cognitive dysfunction in advanced Alzheimer’s disease.; Methods: We evaluated the efficacy and adverse effects of donepezil when the dose was increased to 10 mg/day in 61 Japanese patients with Alzheimer’s disease. Cognitive function was evaluated using the Revised Hasegawa Dementia Scale and mini-mental state examination at the day before starting, and at 4, 8 and 24 weeks after starting donepezil 10 mg/day. The relationship with apolipoprotein E4 was also investigated.; Results: The Revised Hasegawa Dementia Scale and mini-mental state examination scores were not statistically significantly different at any time after starting donepezil 10 mg/day. It can be anticipated that donepezil 10 mg/day will especially inhibit deterioration of cognitive function in advanced Alzheimer’s disease. The incidence of adverse events was 11.5%, lower than the rate of 40% or higher recorded during previous clinical trials.; Conclusions: The progression of cognitive dysfunction could be inhibited by increasing the dose of donepezil to 10 mg/day. It was suggested that longer-term treatment with 5 mg/day might lead to fewer adverse events when the dose is increased to 10 mg/day.;

Bibtex Citation

@article{NOZAWA_2009, doi = {10.1111/j.1479-8301.2009.00291.x}, url = {}, year = 2009, month = {jun}, publisher = {Wiley-Blackwell}, volume = {9}, number = {2}, pages = {50--55}, author = {Motohiro NOZAWA and Yosuke ICHIMIYA and Eiko NOZAWA and Yushi UTUMI and Hideki SUGIYAMA and Norio MURAYAMA and Eizo ISEKI and Heii ARAI}, title = {Clinical effects of high oral dose of donepezil for patients with Alzheimer{textquotesingle}s disease in Japan}, journal = {Psychogeriatrics} }


administration & dosage, adverse effects, aged, alzheimer disease, apolipoprotein e4, cholinesterase inhibitors, cognition, disease progression, donezepil, drug administration schedule, drug effects, drug therapy, female, genetic predisposition to disease, genetics, humans, indans, japan, male, nootropic agents, pharmacology, piperidines

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Before and After Study

Type of Outcomes

Adverse Events

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime